About ProKidney Corp. - Class A Ordinary Shares (PROK)
ProKidney Corp. is a biotechnology company focused on developing innovative therapies for chronic kidney disease. The company aims to improve patient outcomes by advancing regenerative medicine solutions that address the underlying causes of kidney dysfunction. ProKidney's research emphasizes harnessing the power of cellular therapies to restore normal kidney function and alleviate the burden of this prevalent condition. Through its commitment to scientific excellence and patient-centric approaches, ProKidney strives to transform the landscape of kidney disease treatment and support the well-being of patients worldwide. Read More
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference:
The treatment, rilparencel, showed a 78% improvement in kidney function decline in one dosing group, with no serious safety issues reported, supporting its ongoing evaluation in a larger Phase 3 trial.
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours to $4.05 on positive Phase 2 trial results, with trading volume seeing a jump to 39.8 million shares from an average of 1.12 million.
U.S. major indices ended mixed on Tuesday, as the Dow Jones Industrial Average slipped nearly 0.4% to 44,240.76 and the S&P 500 edged down 0.1% to 6,225.52.
ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with chronic kidney disease and diabetes.
WINSTON-SALEM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial evaluating rilparencel in patients with CKD and diabetes. Rilparencel is an autologous cellular therapy that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food & Drug Administration (FDA) and is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and (ii) each Class B ordinary share automatically converted into one share of Class B common stock of ProKidney. ProKidney common stock will begin trading on July 2, 2025, and the Company's trading symbol on the Nasdaq Stock Market will remain unchanged as "PROK." The Company’s CUSIP number relating to its Class A common stock changed to 74291D 104. The Company does not anticipate any impact to day-to-day business operations as a result of the domestication.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
